

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 DECEMBER 2023

The board of directors (the “**Board**”) of Sinopharm Tech Holdings Limited (the “**Company**”) is pleased to announce that at the annual general meeting of the Company held on 22 December 2023 (the “**AGM**”), all proposed resolutions (the “**Resolutions**”) as set out in the notice of the AGM dated 23 November 2023 were duly passed by the shareholders of the Company by way of poll. All directors of the Company attended the AGM in person or by electronic means.

The poll results in respect of all the Resolutions are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements, the directors’ report and independent auditors’ report of the Company for the year ended 30 June 2023	28,094,644 (99.99%)	2,800 (0.01%)
2.	a. To re-elect Mr. CHAU Wai Wah Fred as an executive director	28,097,444 (100.00%)	0 (0.00%)
	b. To re-elect Mr. LAU Fai Lawrence as an independent non-executive director	28,097,444 (100.00%)	0 (0.00%)
	c. To re-elect Mr. HSU Dong An as an independent non-executive director	28,097,444 (100.00%)	0 (0.00%)
	d. To re-elect Mr. HEUNG Pik Lun as an independent non-executive director	28,097,444 (100.00%)	0 (0.00%)

	e.	To authorize the Board to fix the directors' remuneration	28,097,444 (100.00%)	0 (0.00%)
3.		To re-appoint Elite Partners CPA Limited as auditors of the Company and to authorize the Board to fix their remuneration	28,097,444 (100.00%)	0 (0.00%)
4.		To grant a general mandate to the directors to issue, allot and otherwise deal with the shares of the Company	28,094,644 (99.99%)	2,800 (0.01%)
5.		To grant a general mandate to the directors to repurchase the shares of the Company	28,097,444 (100.00%)	0 (0.00%)
6.		To add the total number of the shares repurchased by the Company to the mandate granted to the directors under resolution no. 4	28,094,644 (99.99%)	2,800 (0.01%)
Special Resolution				
7.		To approve the proposed amendments to the existing amended and restated memorandum and articles of association of the Company and adopt the second amended and restated memorandum and articles of association of the Company	28,094,644 (99.99%)	2,800 (0.01%)

As more than 50% of the votes were cast in favour of each of the ordinary resolutions, all the ordinary resolutions were duly passed at the AGM.

As more than 75% of the votes were cast in favour of the special resolution, the special resolution was duly passed at the AGM.

As at the date of the AGM, the issued share capital of the Company comprised 183,693,055 shares entitling the shareholders of the Company to attend and vote on the Resolutions at the AGM. No shareholder was entitled to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 17.47A of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and no shareholder was required under the GEM Listing Rules to abstain from voting.

Elite Partners CPA Limited, the auditors of the Company, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 22 December 2023

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.